Background: The aim of the study was to examine prevalence of dysphagia at the population level in head and neck cancer (HNC) survivors. Methods: Surveillance, Epidemiology, and End Results-Medicare claims among 16 194 patients with HNC (2002HNC ( -2011 were analyzed to estimate 2-year prevalence of dysphagia, stricture, and aspiration pneumonia, and derive treatment-and site-specific estimates. Results: Prevalence of dysphagia, stricture, pneumonia, and aspiration pneumonia was 45.3% (95% confidence interval [CI]: 44.5-46.1), 10.2% (95% CI: 9.7-10.7), 26.3% (95% CI: 25.6-26.9), and 8.6% (95% CI: 8.2-9.1), respectively. Dysphagia increased by 11.7% over the 10-year period (P < .001). Prevalence was highest after chemoradiation and multimodality therapy. Conclusion: Comparing to published rates using similar methodology the preceding decade (1992)(1993)(1994)(1995)(1996)(1997)(1998)(1999), prevalence of dysphagia based on claims data was similar in 2002-2011 in this study. These results suggest persistence of dysphagia as a highly prevalent morbidity, even in the decade in which highly conformal radiotherapy and minimally invasive surgeries were popularized.
| INTRODUCTION
Dysphagia is a high-impact morbidity of head and neck cancer (HNC). Swallowing difficulty can result from tumor or treatment and adversely impacts both the health 1,2 and quality of life 3, 4 of survivors. Prevalence estimates for dysphagia vary widely in published literature and depend on tumor stage, subsite of disease, age, and treatment modality. Most of the published works in the area of dysphagia derive from single institutional, clinical data sets. Although clinical data offer far superior detail about the nature of dysphagia, small numbers of patients and institutional biases may limit generalizability for inferences about the frequency of dysphagia in the broad population of HNC survivors as well as in clinically relevant subgroups of patients. Population-level data are critical to examine broad outcomes outside academic institutions. Prior population-level
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analyses from the United States often use Surveillance, Epidemiology, and End Results (SEER)-Medicare; these include analyses of feeding tube duration as a function of radiotherapy modality, 5 case-control comparisons of aspiration pneumonia risk after chemoradiation (CRT), 2 examination of dysphagia as a predictor of morbidity, 6 as well as quality studies suggesting positive impact of early speech pathology utilization. 7 Perhaps, the most comprehensive assessment of national HNC trends in dysphagia using the SEER-Medicare database was published by Francis et al. (2010) 8 reporting 3-year prevalence of dysphagia, stricture, and pneumonia of 40%, 7%, and 10%, respectively, among 8002 patients treated between the years 1992 and 1999. Prevalence of all end points was higher among patients requiring multimodality therapy presumably for advanced stages of disease and also among those with pharyngeal primary tumors relative to oral cavity or laryngeal sites. Among all modalities, prevalence of swallowing-related end points was highest in patients who received primary CRT. This comprehensive analysis led to insights about higher risk subgroups of patients and also suggested increasing prevalence of dysphagia-related events over the decade of study (1990's) in an era when organ preservation regimens were intensifying. Since the period of their analysis (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) , the field of head and neck oncology has refined the delivery of surgery and radiotherapy by rapid adoption of both minimally invasive surgical methods (eg, transoral robotic surgery) and highly conformal radiotherapy (RT) planning methods (eg, intensity modulated radiotherapy (IMRT)). Refinements in treatment delivery and other notable shifts including more widespread adoption of proactive supportive care alongside shifting epidemiology of HNC (ie, human papilloma virus-associated HNC) could conceivably impact population-level trends. Therefore, the purpose of this analysis was (1) to reexamine prevalence of dysphagia-related end points in HNC survivors at the population level in a more current decade (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) and (2) to compare prevalence by treatment modalities and site of disease.
| PATIENTS AND METHODS

| Data source
The SEER data were linked to Medicare claims to allow patients aged 65 years or older with HNC patients to be followed longitudinally for information about both the initial diagnosis and downstream medical care. Our linked data set includes cases diagnosed 2002 through 2011 with Medicare claims through 2013 allowing estimation of 2-year prevalence for all eligible cases.
| Cohort selection
This retrospective cohort analysis of SEER-Medicare included patients with (1) 
| Selection of noncancer controls
Noncancer controls for the patients with HNC were selected from the Medicare 5% sample by using 1:1 match based on age, sex, and race/ethnicity of patients with cancer. For each matched control, we used the diagnosis date of its matched cases as its index date; each control was fully covered by Medicare Part A & B from the index date till 28 months after the index date or till the end of the study period if the control was followed up for less than 28 months. Prevalence was computed using the period of 4 months after the index date till 28 months or till the end of the study period if the patient followed up less than 28 months. Of note, 15 439 controls with full Medicare coverage till the end of the 2-year study period were identified to match the 16 194 patients (95.3%). 
| Dysphagia-related outcomes
| Treatment
Four treatment categories were defined including surgery alone, surgery with adjuvant therapy, radiation alone, and RT with chemotherapy. Only index treatment was considered (not salvage surgery or reirradiation). Treatment groups were identified using CPT/Healthcare Common Procedure Coding System, and ICD-9 codes for surgery, radiation, and chemotherapy occurring in the 4 months after cancer diagnosis (Supporting Information Supplementary Table 1 ).
| Covariates
Age at diagnosis, sex (male, female), race, stage at diagnosis, and subsite of disease (oral cavity, oropharynx, hypopharynx, and larynx) were included as covariates in the analysis. Age was categorized into four groups (<69, 69-74, 74-79, and >79 years). Race/ethnicity/origin was classified as non-Hispanic white, Spanish-Hispanic-Latino, black, or other (American Indian/Alaska Native, Asian/Pacific Islander). Stage at diagnosis was coded as available in SEER for the duration of the study period: in situ (no invasion of basement membrane)/localized (confined to organ of origin), regional (extends beyond organ of origin, regional lymph nodes), distant (spread remote from primary tumor), and unstaged. Comorbidities (0-2) were coded by searching inpatient and outpatient claims for diagnostic billing codes for various conditions during the year prior to the diagnosis of cancer, as suggested by Klabunde 9 and by using the Deyo implementation of the Charlson comorbidity score.
10
Comorbidity index was categorized into none, 1, 2, or more.
| Statistical methods
Two-year prevalence and 95% confidence intervals (CIs) were first calculated for each dysphagia-related outcome (dysphagia, stricture, pneumonia, and aspiration pneumonia) among all patients. Prevalence of dysphagia, stricture, pneumonia, and aspiration pneumonia was then estimated for subgroups of patients by tumor site, stage, and treatment modality and compared using the chi-square test. A full model including all patients with HNC plus 4 treatment subgroup multivariable logistic regression models was then fit regressing treatment modality on each dysphagia end point to estimate independent impact of the following treatment scenarios after adjustment for clinicodemographic covariates using a theoretical model building approach retaining all a priori clinically relevant covariates regardless of statistical significance. 11 Acknowledging the diversity of HNC as a clinical population, treatment-subgroup models were evaluated to derive the most clinically plausible effect estimates among more homogeneous groups of patients than the full model combining all HNC cases. Primary treatment modality comparisons from the 4 treatment subgroup multivariable regression models included (1) single modality treatment options (RT alone vs surgery alone), (2) multimodality treatment options (CRT vs surgery + RT), (3) adjuvant radiotherapy (surgery vs surgery + RT), and (4) adjuvant chemotherapy (RT alone vs RT with chemotherapy). Period estimates are reported as adjusted odds ratios (AORs) with 95% CI. Final models included treatment modality, race/ethnicity, age at diagnosis, disease subsite, sex, comorbidity, and disease stage. All P-values are two-sided (α = .05). Statistical analyses were performed using SAS software (version 9.3; SAS Institute, Cary, North Carolina).
3 | RESULTS
| Cohort characteristics
A total of 16 194 patients were included in the analysis. The median age was 74 years, and 65.4% were male. The most common tumor subsites were oral cavity (39.3%) and laryngeal/hypopharyngeal (34.1%) followed by oropharyngeal cancers (8%). Treatment modalities were fairly evenly distributed; approximately half (51.1%) underwent single modality therapy (surgery or RT alone) and the remaining 48.9% underwent multimodality therapy (surgery + adjuvant or CRT). Cohort characteristics are detailed in Table 1 .
| Prevalence of dysphagia-related outcomes among all HNC survivors
Dysphagia, stricture, and aspiration pneumonia were highly prevalent occurring among 45.3% (95% CI: 44. Site of disease (P ≤ .0001), stage (P < .0001), and treatment modality (P < .0001) significantly influenced prevalence of all end points in univariate analysis, as illustrated in Figure 2 . Combining all sites of HNC, prevalence of all swallowing-related outcomes was highest among those treated with CRT relative to all other treatment modalities. Combining all treatment modalities, prevalence of dysphagia and stricture was highest among patients treated for oropharyngeal cancers, whereas pneumonia was most prevalent among laryngeal/hypopharyngeal and nasopharyngeal subgroups. Oral cavity cases had the lowest prevalence of all dysphagiarelated end points. Site by treatment prevalence is detailed in Table 2 . Treatment modality and stage retained statistical significance for all end points in full multivariate models among all patients, whereas site of disease remained significant for stricture, pneumonia, and aspiration pneumonia but not for dysphagia (Table 3) .
3.4 | Multivariable models comparing prevalence of dysphagia-related outcomes between single modality treatments (n = 8277)
Results of multivariable regression models among the subgroup of 8277 patients treated with single modality therapy (surgery or RT alone) are reported in Supporting Information Supplementary Table 2 and Figure 3 . Adjusted odds of all dysphagia-related outcomes were higher with single modality RT relative to surgery. Relative to single modality surgery, single modality radiation was associated with 1.8 (95% CI: 1.5-2.1), 1.4 (95% CI: 1.0-1.9), and 1.3 (95% CI: 0.99-1.8) greater odds of dysphagia, stricture, and aspiration pneumonia, respectively.
3.5 | Multivariable models comparing prevalence of dysphagia-related outcomes between multimodality treatments (n = 7917)
Results of multivariable regression models among the subgroup of 7917 patients treated with multimodality therapy (surgery + adjuvant or CRT) are reported in Supporting Information Supplementary Table 3 and Figure 3 . Adjusted odds of all dysphagia-related outcomes were higher with CRT relative to surgery + adjuvant therapy. Relative to multimodality surgery + RT, CRT was associated with 1.9 (95% CI: 1.7-2.2), 1.3 (95% CI: 1.1-1.6), and 1.3 (95% CI: 1.1-1.6) greater odds of dysphagia, stricture, and aspiration pneumonia, respectively.
3.6 | Multivariable models estimating impact of adjuvant chemotherapy on prevalence of dysphagiarelated outcomes in nonsurgically treated patients (n = 7617)
Results of multivariable regression models among the subgroup of 7617 patients treated with nonsurgical therapy (RT alone or CRT) are reported in Supporting Information Supplementary Table 4 and in Figure 3 . Adjusted odds of all dysphagia-related outcomes were higher among patients who received adjuvant chemotherapy with RT relative to RT alone. Relative to single modality RT, CRT was associated with 3.1 (95% CI: 2.7-3.6), 2.3 (95% CI: 1.9-2.9), and 1.6 (95% CI: 1.2-2.0) greater odds of dysphagia, stricture, and aspiration pneumonia, respectively.
3.7 | Multivariable models estimating impact of adjuvant treatment after primary surgery on prevalence of dysphagia-related outcomes (n = 8577)
Results of multivariable regression models among the subgroup of 8577 patients treated with primary surgical therapy (surgery alone or surgery + adjuvant) are reported in Supporting Information Supplementary Table 5 and in Figure 3 . Adjusted odds of all dysphagia-related outcomes were higher among patients who received adjuvant therapy with surgery relative to surgery alone. Relative to single modality surgery, surgery + adjuvant therapy was associated with 2.8 (95% CI: 2.4-3.2), 2.0 (95% CI: 1.6-2.5), and 1.7 (95% CI:
2) greater odds of dysphagia, stricture, and aspiration pneumonia, respectively. would be expected to attenuate the magnitude of the differences in prevalence between these reports, suggesting that dysphagia and stricture are more commonly coded in administrative data in the 2000s than they were in the 1990s. It is not possible to know whether this reflects greater numbers of survivors affected by dysphagia, or greater reporting or coding of this outcome with growing awareness in the clinical community. Nonetheless, the persistently high prevalence of dysphagia at the population level in modern survivors is noteworthy as swallowing difficulty is a top driver of decisional regret 4 in survivorship and is a leading source of noncancer mortality in survivorship. 12 These results confirm the excess burden of dysphagia and dysphagia-related conditions (eg, pneumonia) in HNC survivors. Relative to noncancer controls, HNC cases were 4.6-7.8 times more likely to have stricture or dysphagia- related claims and 2.1-3.7 times more likely to have pneumonia or aspiration pneumonia-related claims. These data suggest that the high prevalence of dysphagia observed in HNC cases in this sample do not simply reflect age-related or comorbidity-related swallowing dysfunction, as controls were matched on these factors. Similar to comparisons of noncancer controls previously reported by Xu et al. in a SEER-Medicare analysis focused solely on aspiration pneumonia after CRT for mixed sites of HNC, 2 these estimates appear to largely reflect the impact of HNC and its treatment on dysphagia-related outcomes. Frequency of dysphagia is influenced by many factors: most notably tumor site and treatment modality. In 4 treatment subgroups, multivariable regression models (adjusted for clinicodemographic confounders) were fit regressing each dysphagia outcome on treatment modality to examine 2 primary questions: first, the impact of surgical vs nonsurgical modalities (1: RT alone vs surgery alone; and 2: CRT vs surgery + adjuvant), and second, the impact of adjuvant therapy (3: RT vs CRT, ie, the added impact of chemotherapy; and 4: surgery alone vs surgery + adjuvant, ie, the added impact of adjuvant RT or CRT). Two expected themes emerged exploring the results of treatment subgroup models. First, odds of dysphagia-related events were higher after primary nonsurgical methods when compared to primary surgery. This finding aligns with the trends observed in the similar 1990's SEER-Medicare analysis of these end points in dysphagia. 8 It is noteworthy that this trend persisted in the decade (in the 2000s) when IMRT and other highly conformal methods of radiotherapy were popularized with the goal of toxicity reduction. Second, subgroup analyses confirmed that odds of dysphagia-related events were Abbreviations: NPC, nasopharyngeal cancer; OPC, oropharyngeal cancer; CRT, chemoradiation; NR, numbers of patients not reported for cells in which n ≤ 11 observations contributed to the estimate; RT, radiation therapy. Bold cells denote statistically significant differences (P < 0.05). Treatment modality Chemoradiation higher when adjuvant therapy was required (ie, comparing single modality vs multimodality strategies). That is, both the addition of chemotherapy to radiation and the addition of adjuvant therapy after primary surgery were associated with greater prevalence and odds of dysphagia. These trends align with clinical observations and are supported by hosts of clinical and population data supporting excess burden of dysphagia with combined modality (compared to single modality) treatment. 8, 13 Differences in observed effect sizes are perhaps the most notable results from treatment subgroup multivariable analyses. Specifically, as depicted in Figure 3 , effect sizes were largest for addition adjuvant therapy (CRT vs RT alone or surgery + adjuvant vs surgery alone) suggesting 2-to 3-fold increased odds of dysphagia and stricture associated with the addition of adjuvant therapy to either surgery or RT. Effect sizes were much smaller when comparing primary surgical or nonsurgical options for single modality (RT vs surgery alone) or multimodality therapy (CRT vs surgery + adjuvant) suggesting 30%-90% increased odds (<2-fold) of dysphagia or stricture when primary nonsurgical therapy was delivered relative to primary surgical options (AOR: 1.27-1.94, see Figure 3 ). These observations suggest, at least with treatment practices in the 2000s, greater impact of the number of modalities rather than selection of the primary treatment strategy (surgery or radiation) on the prevalence of dysphagia-related outcomes after treatment. This is particularly important when considering strategies to reduce dysphagia burden among patients with low-or intermediate-risk disease, as these population-level data support the notion that the largest impact may be seen with de-escalation strategies that promote a single treatment modality when possible rather than those that simply trade one form of multimodality therapy for another.
Herein, we report updated trends in population-level prevalence of dysphagia in more than 16 000 patients treated for HNC in the United States between 2002 and 2011. Strengths of this analysis include large numbers offering the ability to yield narrow CI from estimates of multivariable models derived from clinically relevant subgroups of patients. We must acknowledge a number of caveats inherent to use of the SEER-Medicare database for these analyses. First, prevalence estimates may be inflated because we analyzed an older cohort of Medicare beneficiaries (age >65 years) as clinical series report age as the most discriminant demographic factor predicting poor swallowing outcomes.
14 Rising prevalence as shown in Figure 1 occurred in an era with significant advances in treatment optimization (such as more conformal RT planning like IMRT and rising utilization of minimally invasive surgery). This is counterintuitive and may in part reflect better coding over the study period rather than true rise in prevalence. The use of administrative claims to code binary dysphagia outcomes over a 2-year period of observation (ie, ever/ never present) also lacks specificity with regard to the nature, severity, or duration of dysphagia events. Likewise, events must be coded on a claim to be coded in the analysis and claims data likely are not sensitive to milder toxicity events. Finally, cancer stage is a major driver of dysphagia outcomes, particularly primary tumor stage (or T-classification), but analysis of stage as a relevant covariate is limited using SEER-Medicare as their cancer staging (localized, regional, and distant) is not compatible with the clinical standard of the American Joint Committee on Cancer system. Limiting the sample to 2004 onward (when full staging is available in SEER) would have allowed more relevant analysis of this covariate but would also have limited sufficient sample size to examine all subgroup trends. This should be considered in future work.
It is also noteworthy that inferences regarding effect sizes, statistical significance, and direction of effects were most consistent between related end points of dysphagia and stricture. Pneumonia and aspiration pneumonia performed less consistently, and subgroup trends were not always compatible between these outcomes. As an outcome, aspiration pneumonia trended more similarly with stricture and dysphagia, whereas general pneumonia diverged in subgroup analyses both by tumor site and treatment modality. These observations support the use of the aspiration pneumonia codes as most specific to dysphagia-related end points.
| CONCLUSION
Updated population-level analysis using SEER-Medicare data find that prevalence of dysphagia, stricture, and aspiration pneumonia remains high in the decade studied (2002-2011) when comparing to published rates using similar methodology in an earlier decade (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) . These results suggest persistence of this morbidity in the decade in which highly conformal radiotherapy methods and minimally invasive surgery were popularized. Prevalence of each dysphagia-related end points was highest among those treated with combined modality RT with chemotherapy. As expected, multivariable models also indicated that odds of dysphagia-related end points were higher among patients treated with multimodality therapy compared to single modality whether primary treatment was surgical or nonsurgical. Finally, larger effect sizes for the impact of adjuvant therapy (ie, single modality vs multimodality regimens) rather than modality (nonsurgical vs surgical modalities) support the notion that de-escalation strategies that promote a single treatment modality rather than those that simply trade one form of multimodality therapy for another could have largest impact on toxicity reduction for swallowing.
